Search bioRxiv⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/2024.12.20.629740

Anti-Cancer Immune Priming with Beta-Radioligand Therapy and Isoform-Selective Targeting of 4Ig-B7-H3

Glazer, S. E.·Sutton, M. N.·Yang, P.·Pisaneschi, F.·Sebastian, M. M.·Gammon, S. T.·Piwnica-Worms, D.
View original source ↗Export metadata ↓

Abstract

Radioligand therapy (RLT), a re-emerging oncologic strategy using molecularly-targeted therapeutic radioisotopes, clinically reduces tumor burden and enhances survival for select patients with otherwise unresponsive advanced prostate cancer and neuroendocrine tumors. Developing new approaches to next generation targets and a better understanding of systemic immune effects could broaden the impact of RLT. Aside from contributions to immune checkpoint, B7-H3 (CD276) is an attractive oncologic target because of its widespread and high differential expression across a variety of solid tumors compared to normal tissues. However, B7-H3 has two isoforms: a 4Ig-B7-H3 isoform, the dominant transmembrane protein expressed on tumors and tumor immune microenvironments (TIME), and a 2Ig-B7-H3 isoform, a soluble ectodomain protein, representing a circulating, and in the context of RLT, significant shed (decoy) antigen. To enhance tumor-specific binding and circumvent confounding soluble 2Ig-B7-H3, a novel IgG2a monoclonal antibody (MIL33B) was generated with high affinity for 4Ig-B7-H3 (72 picomolar) and 8- to 18-fold selectivity over soluble 2Ig-B7-H3. Live cell fluorescence microscopy using AF594-labeled MIL33B demonstrated strong membranous localization and target specificity. PET-CT imaging with 89Zr-labeled MIL33B confirmed robust tumor-selective target binding in vivo in murine xenograft (HeLa cervical) and syngeneic tumor models (4T1 breast, B16F10 melanoma, and CT26 colorectal) expressing human 4Ig-B7-H3. As a single dose beta-emitting systemic RLT therapeutic, 90Y-labeled MIL33B (100 Ci) produced 53% long-term survival in a 4Ig-B7-H3-dependent manner in an otherwise fatal established CT26 colorectal tumor model. Immunologic analysis showed that 90Y-MIL33B RLT functioned as an immune priming event, engaging downstream CD8+ T-cell activation and inducing immunological memory in vivo, thus illustrating the potential of systemic beta-RLT to target both primary and metastatic sites. Thus, MIL33B showcases a strategy to selectively target 4Ig-B7-H3 for beta-RLT, warranting further investigation as an immune priming tactic alone or in combination for cancer therapy. Statement of significanceModest antigen expression levels, even if target tissue-selective, combined with ectodomain shedding (soluble decoy antigens) can generally hinder targeted diagnostic and therapeutic strategies, but are especially challenging for radioligand therapy, PET imaging, and in vivo diagnostics wherein high specific activity radioisotopes necessitate use of low masses of biocarrier. Binding, absorption and non-specific tissue deposition of radiolabeled biocarriers by decoy antigens can significantly misdirect systemic radiation, reducing therapeutic efficacy. An antibody development process with a focus aimed at on-target affinity for folded proteins on live cells resulted in a novel picomolar affinity antibody selectively targeting membranous 4Ig-B7-H3 over soluble decoy 2Ig-B7-H3. This antibody shows promise as a transformative systemic beta-radioligand therapy platform for immune priming applications in oncology, and potentially in cardiology, rheumatology, and autoimmunity.

Explore related subjects

cancer biologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Glazer, S. E., Sutton, M. N., Yang, P., Pisaneschi, F., Sebastian, M. M., Gammon, S. T., Piwnica-Worms, D.. 2024-12-22. Anti-Cancer Immune Priming with Beta-Radioligand Therapy and Isoform-Selective Targeting of 4Ig-B7-H3. https://doi.org/10.1101/2024.12.20.629740

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Tet2-Clonal Hematopoiesis Promotes Whereas Dnmt3a-CH Inhibits Breast Cancer Progression During Aging

Clonal hematopoiesis of indeterminate potential (CHIP) driven by somatic mutations in blood cells increases with age and is associated with adverse outcomes in cancer patients. How CHIP mutations influence solid tumor progression remains unclear. Using inducible murine models of Dnmt3a- or Tet2-mutant CHIP combined with orthotopic syngeneic breast cancer models, we demonstrate that upon aging Dnmt3a-mutant CHIP prevents whereas Tet2-mutant CHIP drives breast cancer progression. Dnmt3a-mutant immune infiltrates established interferon-mediated MHCIIhigh tumor-associated macrophages (TAMs) that supported cytotoxic CD8+ T cell-mediated tumor rejection. In contrast, Tet2-mutant TAMs exhibited an inflammatory, immunosuppressive phenotype characterized by increased IL-1 and CXCL2 production, reduced MHCII expression, and impaired T cell recruitment and activation. Therapeutic blockade of IL-1R1 or CXCR2 reduced tumor progression in aged Tet2-mutant CHIP mice and partially restored anti-tumor immunity. These findings establish that the effects of CHIP on cancer are mutation- and age-dependent and identify IL-1/CXCL2-driven inflammation as a therapeutic vulnerability of tumor-promoting Tet2-mutant CHIP.

cancer biology↗
bioRxiv2026

Single Nucleus Profiling Reveals Rewired Tumor-Immune-Stromal Cell Communication in Plasmacytoid Urothelial Carcinoma

Plasmacytoid urothelial carcinoma (PUC) is an aggressive histologic subtype of bladder cancer associated with worse patient outcomes and therapeutic response compared to conventional urothelial carcinoma (CUC). While recent work has demonstrated metastatic lymph nodes from PUC tumors have an inflamed phenotype, how the tumor microenvironment (TME) and crosstalk between tumor, stromal, and immune cells in primary PUC bladder tumors differs from those in CUC remains poorly understood. The impact of these differences on response to immunotherapy is also unknown. To understand TME differences between CUC and PUC and their impact on cell signaling, we performed single nucleus RNA sequencing on PUC and CUC tumors, as well as Xenium spatial transcriptomics on a mixed CUC / PUC tumor. We identified increased signaling between PUC-enriched, CDH1-low urothelial cells, immunosuppressive lipid-associated macrophages, and SFRP2+/CTHRC1+ fibroblasts in PUC tumors compared to CUC. Spatial transcriptomics identified increased macrophage infiltration in PUC histology and colocalization of PUC tumor cells, immunosuppressive macrophages, and SFRP2+ fibroblasts. Taken together, this study delineates PUC architecture and demonstrates interplay CDH1-low tumor cells, EMT, and immunosuppressive macrophages, identifying possible therapeutic vulnerabilities in PUC.

cancer biology↗
bioRxiv2026

The Phospholipase A2 Activity of Peroxiredoxin 6 Protects Hepatocarcinoma Cells Against Ferroptosis and Mitophagy Impairment

Peroxiredoxin 6 (PRDX6) is a moonlighting protein that plays a key role in regulating redox homeostasis and lipid metabolism through its unique dual peroxidase and calcium-independent phospholipase A2 (iPLA2) activities. Here, we generated a stable HepG2 cell line harboring a D140A mutation to selectively ablate iPLA2 activity, and we compared its phenotype with that of wild-type (WT) and PRDX6-knockout (KO) cells. D140A exhibited low ROS leves, similar to WT cells, confirming that oxidative stress is due to peroxidase deficiency. In contrast, D140A cells displayed higher lipid peroxidation than WT cells, though significantly lower than that of KO cells. Furthermore, the D140A mutant mirrored the KO phenotype regarding intracellular ferrous iron accumulation, impaired lipid droplet biogenesis, and the downregulation of the key ferroptosis regulator GPX4. Mechanistically, integrated proteomic, lipidomic, and enzymatic analyses revealed that a deficiency in iPLA2 activity of PRDX6 disrupted the release of key lipid species necessary for cell structure and signaling. Consequently, organelles involved in lipid synthesis and trafficking, such as peroxisomes, endoplasmic reticulum, mitochondria and lipid droplet, were affected. Specifically, we found that mitochondria exhibited a reduction in cristae and a diminished capacity for mitophagy and autophagy, which ultimately makes cells much more susceptible to erastin-induced ferroptotic cell death. Taken together, our findings demonstrate that PRDX6 iPLA2 activity uniquely coordinates organelle lipid homeostasis and mitophagy to protect cancer cells from ferroptotic cell death. Consequently, the use of iPLA2 inhibitors such as MJ33, which decreased PRDX6 iPLA2 activity to a level comparable to the mutant D140A, could represent a promising therapeutic strategy for inducing ferroptotic cell death in hepatocellular carcinoma.

cancer biology↗